Raras
Buscar doenças, sintomas, genes...
Mastocitose cutânea
ORPHA:66646CID-10 · D47.01CID-11 · 2A21.1OMIM 154800DOENÇA RARA

Mastocitose cutânea é um termo que se refere a um grupo de doenças caracterizadas pelo acúmulo e proliferação anormais de mastócitos na pele. Em alguns casos (mais comumente em adultos), a mastocitose cutânea pode ocorrer em associação com infiltração de mastócitos em vários órgãos extracutâneos, caso em que o distúrbio é denominado mastocitose sistêmica.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Mastocitose cutânea é um termo que se refere a um grupo de doenças caracterizadas pelo acúmulo e proliferação anormais de mastócitos na pele. Em alguns casos (mais comumente em adultos), a mastocitose cutânea pode ocorrer em associação com infiltração de mastócitos em vários órgãos extracutâneos, caso em que o distúrbio é denominado mastocitose sistêmica.

Pesquisas ativas
1 ensaio
10 total registrados no ClinicalTrials.gov
Publicações científicas
764 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
Childhood
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D47.01
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧬
Pele e cabelo
14 sintomas
🫃
Digestivo
7 sintomas
🩸
Sangue
3 sintomas
🦴
Ossos e articulações
2 sintomas
👁️
Olhos
1 sintomas
🫁
Pulmão
1 sintomas

+ 25 sintomas em outras categorias

Características mais comuns

Hemorragia gastrointestinal
Herança autossômica dominante
Lesões cutâneas pigmentadas profusas
Hepatomegalia
Edema
Mácula hiperpigmentada
54sintomas
Sem dados (54)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 54 características clínicas mais associadas, ordenadas por frequência.

Hemorragia gastrointestinalGastrointestinal hemorrhage
Herança autossômica dominanteAutosomal dominant inheritance
Lesões cutâneas pigmentadas profusasProfuse pigmented skin lesions
HepatomegaliaHepatomegaly
Edema

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico764PubMed
Últimos 10 anos200publicações
Pico202345 papers
Linha do tempo
2026Hoje · 2026🧪 1999Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.

KITMast/stem cell growth factor receptor KitDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulator

LOCALIZAÇÃO

Cell membraneCytoplasm

VIAS BIOLÓGICAS (5)
Developmental Lineage of Mammary Gland Luminal Epithelial CellsDevelopmental Lineage of Mammary Gland Alveolar CellsTFAP2 (AP-2) family regulates transcription of growth factors and their receptorsSignaling by SCF-KITRegulation of KIT signaling
MECANISMO DE DOENÇA

Piebald trait

Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
44.5 TPM
Ovário
36.4 TPM
Esôfago - Junção
35.3 TPM
Cérebro - Hemisfério cerebelar
29.8 TPM
Tireoide
28.1 TPM
OUTRAS DOENÇAS (21)
gastrointestinal stromal tumorcutaneous mastocytosisacute myeloid leukemiapiebaldism
HGNC:6342UniProt:P10721

Variantes genéticas (ClinVar)

342 variantes patogênicas registradas no ClinVar.

🧬 KIT: NM_000222.3(KIT):c.620-2A>G ()
🧬 KIT: NM_000222.3(KIT):c.2307del (p.Leu769fs) ()
🧬 KIT: NM_000222.3(KIT):c.438T>A (p.Tyr146Ter) ()
🧬 KIT: NM_000222.3(KIT):c.1801G>A (p.Gly601Arg) ()
🧬 KIT: NM_000222.3(KIT):c.2306dup (p.Leu769fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 42 variantes classificadas pelo ClinVar.

13
29
Patogênica (31.0%)
VUS (69.0%)
VARIANTES MAIS SIGNIFICATIVAS
KIT: NM_000222.3(KIT):c.590C>T (p.Ser197Leu) [Conflicting classifications of pathogenicity]
KIT: NM_000222.3(KIT):c.1231+13A>T [Conflicting classifications of pathogenicity]
KIT: NM_000222.3(KIT):c.555T>G (p.His185Gln) [Conflicting classifications of pathogenicity]
KIT: NM_000222.3(KIT):c.2138C>T (p.Ser713Phe) [Conflicting classifications of pathogenicity]
KIT: NM_000222.3(KIT):c.867G>A (p.Met289Ile) [Conflicting classifications of pathogenicity]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 21
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 7 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Mastocitose cutânea

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

10 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
387 papers (10 anos)
#1

Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value.

Frontiers in cell and developmental biology2026

Mastocytosis is a rare clonal hematological neoplasm, characterized by cutaneous manifestations in children and categorized as: maculopapular cutaneous mastocytosis (MPCM), diffuse cutaneous mastocytosis (DCM) and mastocytoma. Systemic mastocytosis (SM) typically occurs in adults with c-KIT D816V mutation. Additional genetic mutations (TET2, NRAS, SF3B1, ASXL1, etc.) have been detected using Next-Generation Sequencing (NGS) in the adult population while limited information is available in the pediatric setting. 36 patients (pts) with pediatric mastocytosis diagnosed between 1997 and 2021 were included. Peripheral blood samples were collected to detect c-KIT D816V mutation, using both RT-PCR and ddPCR techniques, and to investigate other molecular mutations using NGS panel for rare and myeloid genes. Median age of lesion onset was 4.7 months (range birth-17.8 years). 58% of the cohort underwent cutaneous biopsy after a median 3.77 months from lesion onset (range 2.49 months-11.6 years). 20 (55%) were classified as MPCM, 10 (28%) as DCM and 6 (17%) as mastocytoma. Median tryptase value at the onset was 5 ng/mL: MPCM (range 1.2-141 ng/mL) vs. DCM (range 2.71-19.4 ng/mL) vs. mastocytoma (range 3.8-7.3 ng/mL). Two MPCM pts developed indolent SM (ISM) after 10 and 20 years from the onset of disease. RT-PCR identified c-KIT D816V mutation in 4 pts (2 MPCM, 1 DCM, 1 ISM). NGS revealed the precedent mutation in 3 pts, c-KIT D816Y and c-KIT Y553C in 2 pts. An additional 10 myeloid gene mutations were detected by NGS: 5 already known (ASXL1 G1397S; JAK2 L393V; c-KIT D816Y; LNK E208Q; TET2 Y867H) and 5 not previously described (ETV6 A215P; c-KIT Y553C; NFE2 I291T; SH2B3 G382D; SH2B3 L438V). A single mutation was found in 7 pts (3 MPCM, 3 DCM, 1 ISM), while two or more mutations in 3 DCM pts. Overall, 9/36 pts (5 DCM, 3 MPCM, 1 mastocytoma) presented spontaneous complete regression of cutaneous lesions after a median time of 25 months (range 17 months-25 years). c-KIT mutations resulted in 35% of the children tested. The RT-PCR technique resulted more sensitive in finding c-KIT D816V, while NGS in detecting other mutations whose prognostic roles require further investigation.

#2

Soluble FcεRI is increased in advanced mastocytosis and acts as a negative regulator of mast cell expansion and activation.

The Journal of allergy and clinical immunology2026 Feb 20

The soluble alpha chain of FcεRI (sFcεRI) is released during receptor cross-linking on mast cells (MCs) and serves as an acceptor site for circulating IgE. Recent data suggest that sFcεRI counteracts MC activation in allergic patients. We measured the levels of sFcεRI and its effect in cutaneous mastocytosis and systemic mastocytosis (SM). sFcεRI levels were quantified by ELISA in 114 patients with mastocytosis, including cutaneous mastocytosis (n = 12), indolent SM (n = 67), smoldering SM (n = 5), SM with associated hematologic neoplasm (n = 17), aggressive SM (n = 9), and MC leukemia (n = 4). We measured sFcεRI levels at diagnosis and during follow-up and established correlations with the SM variant, prognostic parameters, and survival. Moreover, we assessed sFcεRI effects on proliferation of neoplastic MCs and IgE-dependent activation and histamine release in basophils obtained from SM patients. Compared to healthy controls, sFcεRI levels were within normal range in most patients with cutaneous mastocytosis and indolent SM, whereas in most patients with advanced SM, especially those with aggressive SM, increased sFcεRI levels were detected. Moreover, we found that a clearly elevated sFcεRI level in SM correlates with poor survival and a lower risk of vascular instability. sFcεRI levels did not correlate with serum tryptase levels, total IgE levels, or the presence of hereditary α-tryptasemia. In in vitro experiments, sFcεRI suppressed anti-IgE-induced CD63 expression and histamine release in basophils and growth of neoplastic MCs. sFcεRI is often elevated in patients with advanced SM and acts as negative regulator of growth and activation of neoplastic MCs.

#3

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal of the American Academy of Dermatology2026 Feb 12

Indolent systemic mastocytosis (ISM), a clonal mast cell disease driven by the KIT D816V mutation, can often cause debilitating dermatologic symptoms. Assess improvement of ISM-related skin manifestations after treatment with avapritinib, a highly selective KIT D816V inhibitor, vs placebo in Part 2 of the PIONEER study (NCT03731260). Patients with moderate-to-severe ISM received avapritinib 25 mg once daily (n=141) or placebo (n=71). Endpoints included skin lesion area and pigmentation at week 24, skin mast cell burden, and change in symptoms. Mean percent reduction in lesional surface area was -36.6% with avapritinib vs -1.8% with placebo in the most affected area; 86% vs 0% had improved skin lesion color. Mean percent change in skin mast cell burden decreased with avapritinib (-22.1%) vs placebo (10.1%). Avapritinib vs placebo significantly improved skin symptom domain score (mean change -7.2 vs -2.8; p<.0001), including the individual skin symptoms itching, flushing, and spots. Avapritinib was well tolerated. Photography was optional, so analysis population for lesion area and color were smaller (n=111) than the overall study population (n=212). Avapritinib treatment improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion color, and reduced skin mast cell burden in patients with ISM.

#4

ISM-1 expression in cutaneous mastocytosis: Diagnostic potential and comparison with CD117.

Medicine2026 Jan 30

Isthmin-1 (ISM-1) is a multifunctional secreted protein expressed in various tissues, exhibiting biological activities that overlap with mast cell functions. To date, no study has demonstrated its expression in mast cells. This study presents the first evidence of ISM-1 immunoreactivity in mast cells and investigates its diagnostic relevance in cutaneous mastocytosis. Thirty-nine patients diagnosed with cutaneous mastocytosis from 2 tertiary centers were retrospectively evaluated. Formalin-fixed paraffin-embedded skin biopsy specimens were immunohistochemically stained using antibodies against ISM-1 and CD117. Expression levels were semiquantitatively scored, and associations with clinical, histopathological, and demographic variables were statistically analyzed. All cases exhibited ISM-1 positivity, with 69.2% demonstrating high expression. Notably, ISM-1 remained highly expressed in 2 cases with low CD117 immunoreactivity. While ISM-1 showed diagnostic sensitivity and specificity comparable to CD117, its distinct nuclear localization provided enhanced morphological clarity for mast cell identification. Cases with high ISM-1 expression showed increased eosinophil counts; however, this trend did not reach statistical significance. These findings suggest that ISM-1 may serve as a complementary immunohistochemical marker for mast cell detection, particularly in diagnostically challenging cases. Moreover, its nuclear staining introduces a novel morphological feature that may improve histopathological assessment of mastocytosis and warrants further investigation in mast cell-associated disorders.

#5

Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry.

Children (Basel, Switzerland)2026 Jan 19

Background: Mastocytosis is a rare hematologic disorder, classified into cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Understanding age-related differences in presentation and management is essential for individualized care. Methods: Data from patients recruited from the Montreal Children's and Montreal General Hospitals between 2015 and 2024 were analyzed. Descriptive statistics were employed to present patient demographics, clinical characteristics, and medication usage. Statistical analyses included Fisher's exact test for categorical variables and t-tests or non-parametric equivalents for continuous variables. Results: A total of 63 patients were included, comprising 39 children and 24 adults. Children had a median age of 1.9 years, while adults had a median age of 49.3 years. CM was exclusively prevalent in children (100.0%), while SM was more common in adults (45.8%). Adults with SM had a significantly higher median age than CM (49.4 versus 44.7 years, respectively, p = 0.03). Epinephrine use was more frequent in adult SM patients (36.4% versus 0%, respectively, p = 0.03). No pediatric patients required epinephrine for symptom control. Conclusions: This study highlights important clinical differences between pediatric and adult mastocytosis. CM was more common in children while SM predominated in adults and was associated with greater flare severity and higher tryptase levels.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC357 artigos no totalmostrando 196

2026

Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value.

Frontiers in cell and developmental biology
2025

Unexplained Syncope in Mastocytosis: The Role of Early Dermatological Recognition.

Acta dermatovenerologica Croatica : ADC
2026

Soluble FcεRI is increased in advanced mastocytosis and acts as a negative regulator of mast cell expansion and activation.

The Journal of allergy and clinical immunology
2026

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal of the American Academy of Dermatology
2026

ISM-1 expression in cutaneous mastocytosis: Diagnostic potential and comparison with CD117.

Medicine
2025

Journal Club: Mastocytosis: across the spectrum: pathobiology, clinical evaluation, and evolving therapies.

European journal of dermatology : EJD
2026

Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry.

Children (Basel, Switzerland)
2026

Adult-onset cutaneous mastocytosis presenting as vulvar papules.

American journal of obstetrics and gynecology
2026

Key Pediatric Dermatologic Conditions: A Clinical Review: Part I.

Pediatric annals
2026

Mastocytosis: Imaging Spectrum and Diagnostic Insights.

Radiographics : a review publication of the Radiological Society of North America, Inc
2026

Denosumab as a Potential Disease-Modifying Treatment in Indolent Systemic Mastocytosis-Related Osteoporosis.

JCEM case reports
2026

Management of Mastocytosis and Mast Cell Activation in Children.

The journal of allergy and clinical immunology. In practice
2025

Diffuse Cutaneous Mastocytosis with Bullous Presentation: A Rare Case Report.

Indian journal of dermatology
2025

Challenges in Cutaneous Mastocytosis.

Immunology and allergy clinics of North America
2026

Burden of childhood cutaneous mastocytosis: Severity and caregivers' quality of life.

The journal of allergy and clinical immunology. In practice
2025

Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review.

Pediatric dermatology
2025

French guidelines for the management of nonadvanced mastocytosis in adults.

Orphanet journal of rare diseases
2025

Uncommon Presentation of Mastocytosis: Focus on the Xanthelasmoid Variant.

Cureus
2025

Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
2025

Understanding Cutaneous Mastocytosis: A Case Report on the Symptoms and Diagnosis of a Rare Disease.

Cureus
2025

Diagnosis, management and the burden of symptoms of mastocytosis from the physician's perspective: A nationwide study.

British journal of haematology
2025

Real-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.

Journal of medicine and life
2025

Hereditary α-Tryptasemia and Peripheral Blood KIT D816V Mutation in Patients with Pediatric Mastocytosis.

International journal of molecular sciences
2025

The Use of Biologic Therapeutic Regimens in Cutaneous and Systemic Mastocytosis: A Scoping Review.

Journal of drugs in dermatology : JDD
2025

Idiopathic cutaneous Mastocytosis mimicking infantile psoriasis in a six-month-old male: a rare presentation.

Oxford medical case reports
2025

Indolent Mastocytosis and Bone Health: Molecular Mechanisms and Emerging Treatment Options.

International journal of molecular sciences
2025

Telangiectasia Macularis Eruptiva Perstans Following Radiotherapy: Atypical Presentation of a Rare Condition.

Cureus
2025

Mastocytosis: Part II: Diagnosis and Management of Mastocytosis through a Multidisciplinary Lens.

Journal of the American Academy of Dermatology
2025

Mastocytosis: Part I: Pathogenesis, Clinical Presentation and Classification.

Journal of the American Academy of Dermatology
2025

Prevalence of myeloid gene alterations in paediatric cutaneous and systemic mastocytosis.

British journal of haematology
2025

Telangiectatic Mastocytosis: If It Is Not Mastocytosis, What Is It? Comment on Brockow et al. Challenges in the Diagnosis of Cutaneous Mastocytosis. Diagnostics 2024, 14, 161.

Diagnostics (Basel, Switzerland)
2025

Laser Therapy for Cutaneous Mastocytosis: A Systematic Review.

Journal of cutaneous medicine and surgery
2025

Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis.

JAMA dermatology
2025

Cutaneous mastocytosis: diagnostic challenges and dietary influences.

Dermatology reports
2025

Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients.

American journal of clinical dermatology
2025

Rapid clinical response to nemolizumab in dermatologic diseases associated with pruritus and burning: A multicenter case series.

Journal of the American Academy of Dermatology
2025

Nodular cutaneous mastocytosis combined with chronic myelomonocytic leukaemia: a case report.

European journal of dermatology : EJD
2025

Pediatric Cutaneous Mastocytosis Mistaken for Non-accidental Ecchymoses: A Systematic Review.

Journal of cutaneous medicine and surgery
2025

A rare case of pediatric cutaneous bullous mastocytosis.

JAAD case reports
2025

Confirmed Systemic Mastocytosis in a Pediatric Patient With Widespread Cutaneous Symptoms.

Pediatrics
2025

Cutaneous Mastocytosis in Pediatric Patients With Skin of Color: A Retrospective Cohort Study.

Pediatric dermatology
2025

Eruptive Syringoma-Clinical, Dermoscopic, and Reflectance Confocal Microscopy Features.

Diagnostics (Basel, Switzerland)
2024

Exploring Pediatric Dermatology in Skin of Color: Focus on Dermoscopy.

Life (Basel, Switzerland)
2025

Evaluation of allergic diseases in children diagnosed with cutaneous mastocytosis.

Allergy and asthma proceedings
2024

Recalcitrant Pustular Dermatosis Successfully Treated With Prolonged Isotretinoin Therapy.

Cureus
2024

Mast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis.

Journal of hematopathology
2025

Recurrent prosthetic mitral valve thrombosis: First report of an unusual feature of systemic mastocytosis, a case report and review of the literature.

Caspian journal of internal medicine
2025

Ocular and palpebral manifestations of mastocytosis: A prospective single-center study.

Annales de dermatologie et de venereologie
2025

Demographics, Types of Patient-Reported Allergic Diseases, and Anaphylaxis in Mastocytosis: A Single-Center US Experience.

The journal of allergy and clinical immunology. In practice
2025

Quantifying Mast Cell and Eosinophil Cellular Density in Skin Biopsy Tissue From Adults With Maculopapular Cutaneous Mastocytosis as Compared With Urticaria and Normal Skin: A Retrospective Histopathologic Study.

The American Journal of dermatopathology
2024

Indolent systemic mastocytosis (ISM) without skin lesions as a recurrent anaphylaxis: a case report study.

Annals of medicine and surgery (2012)
2024

Disseminated cutaneous mastocytosis.

Archives of disease in childhood
2024

Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM.

The journal of allergy and clinical immunology. In practice
2025

Mast Cell Disorders and Hymenoptera Venom-Triggered Anaphylaxis: Evaluation and Management.

The journal of allergy and clinical immunology. In practice
2024

Radiation-associated cutaneous mastocytosis: a case report and review of the literature.

Acta oncologica (Stockholm, Sweden)
2024

Subcellular expression of CD30 in cutaneous mastocytosis-An important factor for targeted treatment.

Journal of cutaneous pathology
2024

A comparison of mast cells in skin biopsies of cutaneous mastocytosis with other inflammatory dermatoses: A study of 33 cases.

Journal of cutaneous pathology
2024

Prevalence and impact of the KIT M541L variant in patients with mastocytosis.

Oncotarget
2024

High-frequency ultrasonography: one of the modern imaging diagnostic methods in dermatology. Authors' own experience and review.

Postepy dermatologii i alergologii
2024

Plasma Protein Profiling to Discern Indolent from Advanced Systemic Mastocytosis.

The Journal of molecular diagnostics : JMD
2025

Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience.

European annals of allergy and clinical immunology
2024

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024.

Journal of the National Comprehensive Cancer Network : JNCCN
2024

Telangiectasia Macularis Eruptiva Perstans in a 55-Year-Old Female With Type 2 Diabetes Mellitus.

Cureus
2024

Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.

Allergy
2024

Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy.

Blood
2024

Clinical characteristics of 81 patients with maculopapular cutaneous mastocytosis: A 10-year experience.

Indian journal of dermatology, venereology and leprology
2024

Genomic and clinical characterization of a familial GIST kindred intolerant to imatinib.

NPJ genomic medicine
2024

[MACULOPAPULAR CUTANEOUS MASTOCYTOSIS HARBORING A KIT MUTATION (ASP419DEL): A CASE REPORT].

Arerugi = [Allergy]
2023

A widespread blistering eruption: diffuse cutaneous mastocytosis.

Dermatology online journal
2023

Dermpath: Eruptive syringoma mimicking cutaneous mastocytosis.

European journal of dermatology : EJD
2024

The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients.

The journal of allergy and clinical immunology. In practice
2024

Epidemiology of mastocytosis: a population-based study (Sweden).

Acta oncologica (Stockholm, Sweden)
2024

Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.

International journal of molecular sciences
2024

Bullous Mastocytosis: A Rare Variant of Diffuse Cutaneous Mastocytosis.

Cureus
2024

COVID-19 infection and vaccination in 92 pediatric patients with cutaneous mastocytosis: A retrospective, cross-sectional study.

Pediatric dermatology
2024

Diffuse Cutaneous Mastocytosis: A Rare Entity and its Dermoscopic Features.

Indian dermatology online journal
2024

Challenges in the Diagnosis of Cutaneous Mastocytosis.

Diagnostics (Basel, Switzerland)
2024

Mastocytosis in the skin in dogs: A multicentric case series.

Veterinary and comparative oncology
2024

Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis.

Journal of the American Academy of Dermatology
2024

Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis.

Case reports in hematology
2024

Idiopathic eruptive macular pigmentation in a pediatric patient and a review of the literature.

Pediatric dermatology
2024

Characteristics of an ethnically diverse cohort of children with pediatric cutaneous mastocytosis: One institution's experience.

Pediatric dermatology
2023

An Unusual Transition from Cutaneous to Systemic Mastocytosis in a Pediatric Patient.

Pediatric allergy, immunology, and pulmonology
2024

No indication of aberrant neutrophil extracellular trap release in indolent or advanced systemic mastocytosis.

Scandinavian journal of immunology
2023

Urticaria pigmentosa and systemic mastocytosis.

Clinical case reports
2023

Review and Updates on Systemic Mastocytosis and Related Entities.

Cancers
2023

Current Challenges in the Diagnosis of Pediatric Cutaneous Mastocytosis.

Diagnostics (Basel, Switzerland)
2024

Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.

British journal of haematology
2023

When Mast Cells Run Amok: A Comprehensive Review and Case Study on Severe Neonatal Diffuse Cutaneous Mastocytosis.

Genes
2023

A Review of the Clinical Features and Management of Systemic Congenital Mastocytosis through the Presentation of An Unusual Prenatal-Onset Case.

Current oncology (Toronto, Ont.)
2023

Diffuse cutaneous mastocytosis in a girl with M541L polymorphism in KIT gene: Response to treatment with imatinib.

Anales de pediatria
2023

Urticaria and mimickers of urticaria.

Frontiers in allergy
2024

Latent Mastocytosis Triggered by COVID-19 Vaccination: A Case Report.

Endocrine, metabolic &amp; immune disorders drug targets
2023

Pediatric and Hereditary Mastocytosis.

Immunology and allergy clinics of North America
2023

Congenital cutaneous mastocytosis mistaken for non-accidental injury.

Pediatric investigation
2023

A familial case of diffuse cutaneous mastocytosis.

The journal of allergy and clinical immunology. In practice
2023

Unusual presentation of maculopapular cutaneous mastocytosis in an infant with skin of color.

JAAD case reports
2023

Telangiectasia Macularis Eruptiva Perstans Treated with Narrow-Band UVB Phototherapy and Heliotherapy during the COVID-19 Pandemic.

Acta medica Philippina
2023

Perioperative management of mastocytosis.

Journal of anesthesia
2023

Clinician awareness of the risk of anaphylaxis in patients with cutaneous mastocytosis.

Clinical and experimental dermatology
2023

Telangiectasia macularis eruptiva perstans associated with multiple myeloma.

European journal of dermatology : EJD
2023

Recalcitrant Cutaneous Mastocytosis Treated With Genetically Informed Targeted Therapy: A Case Report.

International journal of dermatology and venereology
2023

Cutaneous Lesions of Mastocytosis: Mast Cell Count, Morphology, and Immunomolecular Phenotype.

The American Journal of dermatopathology
2023

Cutaneous Mastocytosis in Childhood: An Update from the Literature.

Journal of clinical practice and research
2023

Unusual presentation of telangiectasia macularis eruptiva perstans at the site of healed herpes zoster; Wolf's isotopic response.

The Australasian journal of dermatology
2023

Aggressive systemic mastocytosis of colon and lymph node: A case report.

Medicine
2023

Cutaneous mastocytosis in 8 young dogs and review of literature.

Veterinary pathology
2023

Childhood Cutaneous Mastocytosis: Revisited.

Indian journal of dermatology
2023

[Mastocytosis in children].

Dermatologie (Heidelberg, Germany)
2023

The Role of Mast Cells in the Induction and Maintenance of Inflammation in Selected Skin Diseases.

International journal of molecular sciences
2023

Recent advances in diagnosis and therapy in systemic mastocytosis.

Blood research
2023

Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).

The journal of allergy and clinical immunology. In practice
2023

COVID-19 Vaccines Are Safely Tolerated in Adolescents with Cutaneous Mastocytosis.

International archives of allergy and immunology
2023

Radiotherapy-Associated Cutaneous Mastocytosis in a Patient With Breast Carcinoma. Case Report and Review of the Literature.

The American Journal of dermatopathology
2023

Pediatric Cutaneous Mastocytosis With Motor and Intellectual Delay.

Cureus
2023

[Solitary mast cell tumor. A case comunication].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
2023

Mastocytosis in children: a single-center long-term follow-up study.

International journal of dermatology
2023

Delayed Diagnosis of Indolent Systemic Mastocytosis as the Cause of Unexplained Skin Rash: A Case Report.

Case reports in oncology
2023

Updates in diagnosis and management of paediatric mastocytosis.

Current opinion in allergy and clinical immunology
2023

Comprehensive mastocytosis data analysis from a single center.

BMC cancer
2023

Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.

Italian journal of pediatrics
2023

Lymph node metastasis in feline cutaneous low-grade mast cell tumours.

Journal of feline medicine and surgery
2022

A Case of Systemic Mastocytosis Diagnosed Endoscopically.

Cureus
2022

Pseudoxanthomatous Mastocytosis in a 2-Month Female Infant.

Indian journal of dermatology
2023

Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis.

The journal of allergy and clinical immunology. In practice
2023

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.

Allergy
2022

Diffuse Cutaneous Mastocytosis.

Skinmed
2023

New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.

Annual review of pathology
2023

Mastocytosis and related entities: a practical roadmap.

Acta clinica Belgica
2023

The international consensus classification of mastocytosis and related entities.

Virchows Archiv : an international journal of pathology
2022

Mast Cell Sarcoma of the Retroperitoneum With Concurrent Systemic Mastocytosis and an Undisclosed Associated Hematologic Neoplasm: A Case Report.

Clinical pathology (Thousand Oaks, Ventura County, Calif.)
2022

Dermoscopic Features of Different Forms of Cutaneous Mastocytosis: A Systematic Review.

Journal of clinical medicine
2022

Acute abdomen due to anaphylactic intestinal edema associated with systematic mastocytosis: a case report.

International journal of emergency medicine
2022

Delayed diagnosis of adult-onset mastocytosis.

Proceedings (Baylor University. Medical Center)
2022

The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity.

Frontiers in immunology
2022

Mefloquine causes selective mast cell apoptosis in cutaneous mastocytosis lesions by a secretory granule-mediated pathway.

Experimental dermatology
2022

Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.

Research in veterinary science
2022

Progress of telangiectasia macularis eruptiva perstans exacerbated egg allergy.

Pediatrics international : official journal of the Japan Pediatric Society
2022

Persistent Facial Flushing in a Patient with Telangiectasia Macularis Eruptiva Perstans: An Unusual but Should Emphasized Clinical Finding.

Clinical, cosmetic and investigational dermatology
2022

[A CHILD CASE OF DIFFUSE CUTANEOUS MASTOCYTOSIS].

Arerugi = [Allergy]
2022

Drugs and Vaccines Hypersensitivity in Children with Mastocytosis.

Journal of clinical medicine
2022

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans.

JAAD case reports
2022

A case of cutaneous bullous mastocytosis in a Yorkshire terrier puppy.

Veterinary dermatology
2022

Histopathological characteristics are instrumental to distinguish monomorphic from polymorphic maculopapular cutaneous mastocytosis in children.

Clinical and experimental dermatology
2022

Mastocytosis: Fertility and Pregnancy Management in a Rare Disease.

Frontiers in oncology
2022

Acute increases in total serum tryptase unassociated with hemodynamic instability in diffuse cutaneous mastocytosis.

Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology
2022

Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.

The Journal of allergy and clinical immunology
2022

Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV
2022

Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis.

The Journal of allergy and clinical immunology
2022

The Expressions of CD30 and CD123 of Mastocytosis in Taiwan.

Applied immunohistochemistry &amp; molecular morphology : AIMM
2022

Disseminated tense bullae on newborn.

JAAD case reports
2021

-2518A/G polymorphism of monocyte chemotactic protein 1 (MCP-1/CCL2) is associated with cutaneous mastocytosis.

Postepy dermatologii i alergologii
2022

Cutaneous mastocytosis in a child with a de novo GNB1 mutation.

Pediatric dermatology
2022

Cutaneous mastocytosis in childhood.

Allergologie select
2021

A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years' Experience of the GISM Network.

Cancers
2021

Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder.

Clinical and molecular allergy : CMA
2021

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.

HemaSphere
2021

Pediatric Mastocytosis: An Update.

Mediterranean journal of hematology and infectious diseases
2021

Telangiectasia Macularis Eruptiva Perstans of the Scalp Mimicking Angiosarcoma.

The American Journal of dermatopathology
2021

Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.

International journal of molecular sciences
2021

Mastocytosis-A Review of Disease Spectrum with Imaging Correlation.

Cancers
2021

A Double Histochemical/Immunohistochemical Staining for the Identification of Canine Mast Cells in Light Microscopy.

Veterinary sciences
2021

Clinicopathological Profile of Childhood Onset Cutaneous Mastocytosis from a Tertiary Care Center in South India.

Indian dermatology online journal
2021

Systemic Mastocytosis: Advances in Diagnosis and Current Management.

Cancer treatment and research
2021

Anaphylaxis and epinephrine autoinjector use in pediatric patients with cutaneous mastocytosis.

Pediatric dermatology
2021

Unsatisfactory agreement using current classification of maculopapular cutaneous mastocytosis.

Journal of the European Academy of Dermatology and Venereology : JEADV
2022

Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis.

Blood
2021

Maculopapular Cutaneous Mastocytosis Successfully Treated with Omalizumab.

Acta dermatovenerologica Croatica : ADC
2021

Generalized Eruptive Syringoma in a Nigerian Woman: A Case Report and a Brief Literature Review.

Nigerian journal of clinical practice
2021

Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: A Work Group Report of the AAAAI Allergic Skin Diseases Committee.

The Journal of allergy and clinical immunology
2021

Modulation of dermal equivalent of hypothalamus-pituitary-adrenal axis in mastocytosis.

Postepy dermatologii i alergologii
2022

Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms.

Molecular therapy : the journal of the American Society of Gene Therapy
2021

Cutaneous mastocytosis-Conglomerate of diagnostic tools: A report of four cases.

Indian journal of pathology &amp; microbiology
2021

The novel KIT exon 11 germline mutation K558N is associated with gastrointestinal stromal tumor, mastocytosis, and seminoma development.

Genes, chromosomes &amp; cancer
2021

Case Report and Review of the Literature: Bullous Skin Eruption After the Booster-Dose of Influenza Vaccine in a Pediatric Patient With Polymorphic Maculopapular Cutaneous Mastocytosis.

Frontiers in immunology
2021

Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.

Annals of allergy, asthma &amp; immunology : official publication of the American College of Allergy, Asthma, &amp; Immunology
2021

Expression of MRGPRX2 in skin mast cells of patients with maculopapular cutaneous mastocytosis.

The journal of allergy and clinical immunology. In practice
2021

Poikiloderma With Neutropenia and Mastocytosis: A Case Report and a Review of Dermatological Signs.

Frontiers in medicine
2022

Clinical and Demographic Characteristics of Cutaneous Mastocytosis in Childhood: Single-center Experience.

Journal of pediatric hematology/oncology
2021

Interobserver variability in the classification of childhood maculopapular cutaneous mastocytosis.

Journal of the European Academy of Dermatology and Venereology : JEADV
2021

Genodermatoses in Las Tunas Province, Cuba, 1989-2019.

MEDICC review
2021

Cutaneous Mastocytosis in Childhood-Update from the Literature.

Journal of clinical medicine
2021

Natural evolution in pediatric cutaneous mastocytosis: 10-year follow-up.

International journal of dermatology
2021

Cutaneous Mastocytosis in a Pediatric Dental Patient: Multidisciplinary Approach to Oral Management.

Journal of dentistry for children (Chicago, Ill.)
2021

Diffuse cutaneous mastocytosis masquerading as linear IgA bullous dermatosis of childhood.

Dermatology reports
2021

Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL-1 : why we should investigate further.

The British journal of dermatology
2021

Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.

International journal of molecular sciences
2021

Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis.

International journal of molecular sciences
2021

Medical, neurobiological, and psychobehavioral perspectives of mastocytosis: a case report.

Journal of medical case reports
2021

Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series.

British journal of haematology
2021

Mastocytosis in the skin accompanied by pseudo-Kaposi's sarcoma.

The Journal of dermatology
2021

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis.

The Journal of investigative dermatology
2021

CME suggestions for pediatricians, allergists, and dermatologists, directed by an online survey on urticaria knowledge.

Allergologia et immunopathologia
2021

Diffuse cutaneous mastocytosis: Identification of KIT mutation and long-term follow-up with serum tryptase level.

The Journal of dermatology
2021

Pediatric Mastocytosis: Recognition and Management.

American journal of clinical dermatology
2021

Detection of the germline KIT S476I mutation in a kindred with familial mastocytosis associated with gastrointestinal stromal tumors.

The journal of allergy and clinical immunology. In practice
Ver todos os 357 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Mastocitose cutânea.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Mastocitose cutânea

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value.
    Frontiers in cell and developmental biology· 2026· PMID 41836292mais citado
  2. Soluble Fc&#x3b5;RI is increased in advanced mastocytosis and acts as a negative regulator of mast cell expansion and activation.
    The Journal of allergy and clinical immunology· 2026· PMID 41724406mais citado
  3. Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.
    Journal of the American Academy of Dermatology· 2026· PMID 41690487mais citado
  4. ISM-1 expression in cutaneous mastocytosis: Diagnostic potential and comparison with CD117.
    Medicine· 2026· PMID 41630249mais citado
  5. Comparative Analysis of Pediatric and Adult Mastocytosis: Clinical Presentation, Triggers, and Treatment Patterns from a Tertiary Care Registry.
    Children (Basel, Switzerland)· 2026· PMID 41597149mais citado
  6. A successful treatment of urticaria pigmentosa with omalizumab in a pediatric patient: a case report.
    AME Case Rep· 2026· PMID 41971936recente
  7. Reconsidering cytoreductive therapy in high-risk pediatric mastocytosis: From diffuse cutaneous to smoldering systemic disease.
    J Allergy Clin Immunol Glob· 2026· PMID 41958536recente
  8. Unexplained Syncope in Mastocytosis: The Role of Early Dermatological Recognition.
    Acta Dermatovenerol Croat· 2025· PMID 41804626recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:66646(Orphanet)
  2. OMIM OMIM:154800(OMIM)
  3. MONDO:0019023(MONDO)
  4. GARD:7842(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q3851645(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Mastocitose cutânea
Compêndio · Raras BR

Mastocitose cutânea

ORPHA:66646 · MONDO:0019023
Prevalência
Unknown
Herança
Not applicable
CID-10
D47.01 · Outras neoplasias de comportamento incerto ou desconhecido dos tecidos linfático, hematopoético e tecidos correlatos
CID-11
Ensaios
1 ativos
Início
Childhood
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0024900
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades